Jingsong Wang, MD, PhD, is CEO of Harbour Biomed. Before founding HBM, he was the Head of China Research and Development and of Translational Medicine, Asia Pacific, for Sanofi. Dr. Wang joined Sanofi from Bristol-Myers Squibb, where he served in multiple roles including Director of Discovery Medicine and Clinical Pharmacology and Global Program Lead for pre-clinical and clinical assets. Dr. Wang completed his Clinical Rheumatology Fellowship and was an Attending Rheumatologist and faculty member at Brigham and Women's Hospital and Harvard Medical School. Dr. Wang earned his PhD in Molecular Pharmacology from China Pharmaceutical University and also completed a Molecular Immunology Research Fellowship at the Harvard School of Public Health.

Tony Guo, PhD, is Executive Director, Head of Biometrics China, for the Chinese biotech company BeiGene. Before joining BeiGene, Dr. Guo served as Senior Director, Head of AP Statistics Group, for Merck Research Laboratories. He also worked for Sanofi China as Manager of the Statistics Group and Lead Statistician. Dr. Guo holds adjunct teaching positions in Beijing Normal University, and is Chair of DIA China Statistics Community, a member of the China Clinical Trial Statistics Working Group, and Secretary General of the Beijing Biometrics Association. Dr. Guo earned his PhD in Statistics from North Carolina State University. His research focuses on statistical inference, benefit-risk assessment, missing data analysis, and adaptive design.

Jing CHEN graduated in Pharmaceutical from China Pharmaceutical University and has been working as a QA professional in Pharmaceutical industry since February 2004. Being the mainstay in the QA team in China, she has over 16 years’ QA and auditing experience with AstraZeneca, Quintiles and UCB. Her experiences spans GCP, GCLP and GMP regulated area in both Asia Pacific and Europe. She is now QA Director with LinkStart, and is responsible for the delivery of Quality Assurance and training activities within the company.

Yue WANG is Vice President of ClinPlus, the leading SMO in China. Yue has more than 9 years experience in clinical research operations, over 4 years experience of nursing in Canada. She handled about 20+ multinational projects, including Phase II, Phase III study, Phase IV Study, etc., related to the diseases of Endocrinology, Oncology, Infection, Cardiovascular, etc. Yue is Vice Chair of DIA China SMO Community and once was Young Member, Advisory Council of China, DIA Yue owns CCRC (Certified clinical research coordinator), IACRN